Answers are grounded in this paper and cite their sources.
Commentary highlights biomarkers for apoptosis detection in ischemic stroke and neurodegenerative diseases, suggesting improved clinical applications.
Even as the Serrano-Heras et al. study pinpoints the potential of ApoBDs as biomarkers, constraints to the procedure under consideration pose the threat of bias in future studies. Proper isolation of ApoBDs requires multimodal confirmation, optimized platelet removal protocols and clinically feasible methods like SEC are essential to enhance ApoBDs isolation for neurological disease diagnostics. Rectification of such issues enhance significantly the practicality of ApoBDs in clinical practice for the detection of neurological illnesses.
No takes yet. Share an insight, caveat, or question.
Soleymani-nejadian et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: